Accessibility Menu
MediWound logo

MediWound(NASDAQ) MDWD

Market Cap$163.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-90%
5 Year-49%
1 Year-25%
1 Month-12%
$12.69
+0.24%
+0.03Today
After hours$12.61-$0.08 (-0.63%)
MediWound last closing stock price
MetricPriceDate
Last closeUSD 12.662026-08-28
MediWound stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.16%USD 13.212026-08-21
1 month-11.78%USD 14.352026-07-29
3 month-11.65%USD 14.332026-05-29
Year to date-31.42%USD 18.462025-12-31
1 year-24.73%USD 16.822025-08-28
3 year+49.12%USD 8.492023-08-29
5 year-49.34%USD 24.992021-08-27
Since inception-89.53%USD 120.892014-03-20

MediWound Financials at a Glance

Market Cap

$163.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.86M

Net Income (TTM)

-$20.18M

EPS (TTM)

-$1.60

P/E Ratio

-7.89

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$12.69

Volume

167,024.688

Open

$12.67

Previous Close

$12.61

Daily Range

$12.55 - $12.95

52-Week Range

$12.52 - $20.30

Estimated Earnings Date

Nov 19, 2026

MDWD News

featured-earnings-leadership-highlights.png

MediWound Revenue Jumps 43% in Q2

Motley Fool Markets TeamAug 14, 2025
longview3_large_large_large_large

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

Leo SunMay 21, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediWound

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative solutions for tissue repair and regeneration. The company operates internationally, offering products designed to address complex medical needs, particularly in the field of wound care.

Products and Services
  • NexoBrid: A biopharmaceutical for removing eschar in burn patients
  • EscharEx: A bromelain-based therapy for chronic and hard-to-heal wounds
  • MW005: A biological product candidate for treating non-melanoma skin cancers
Growth Outlook
  • Expansion into new markets is anticipated to drive revenue growth
  • Continued development of innovative therapies may enhance product offerings
  • Strategic partnerships could accelerate market penetration and visibility
Financial Highlights
  • Q2 2026 revenue of $3.09 million, a significant increase from Q1 2026
  • Trailing twelve months (TTM) gross profit margin of 15.46%, indicating operational efficiency
  • Current ratio of 2.32, reflecting strong liquidity and financial health
MediWound Ltd. has established itself as a key player in the biotechnology sector, particularly in wound care. The company's flagship product, NexoBrid, addresses a critical need in burn treatment, while EscharEx and MW005 represent promising advancements in chronic wound management and skin cancer treatment. The recent revenue growth signals a positive trajectory, supported by a robust liquidity position. As the company continues to innovate and expand its market presence, it may attract further interest from investors looking for opportunities in the healthcare sector.
AI Generated • Aug 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

121

CEO

Ofer Gonen

Website

www.mediwound.com

Headquarters

Yavne, HM 8122745, IL

MDWD Financials

Key Financial Metrics (TTM)

Gross Margin

15.46%

Operating Margin

-267.86%

Net Income Margin

-170.10%

Return on Equity

-47.24%

Return on Capital

-48.82%

Return on Assets

-28.07%

Earnings Yield

-12.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$163.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.91M

Volume

167.02K

Avg. Volume

86.44K

Financials (TTM)

Gross Profit

$1.83M

Operating Income

-$31.78M

EBITDA

-$19.00M

Operating Cash Flow

-$22.00M

Capital Expenditure

-$6.38M

Free Cash Flow

-$28.39M

Cash & ST Invst.

$35.34M

Total Debt

$9.54M

MediWound Performance Analysis

MediWound annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 26,496,00011.5%
20232023-12-31USD 18,686,000-29.5%
20242024-12-31USD 20,222,0008.2%
20252025-12-31USD 16,959,000-16.1%
MediWound sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.9%
Q42025-12-31-65.6%
Q12026-03-31-21.0%
Q22026-06-30109.6%
MediWound annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.9312.9%
20232023-12-31USD -0.75-81.0%
20242024-12-31USD -3.03307.3%
20252025-12-31USD -2.10-30.8%
MediWound sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3080.5%
Q42025-12-31-133.3%
Q12026-03-3158.9%
Q22026-06-30-147.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.09M

-45.8%

Gross Profit

$337.00K

-74.9%

Gross Margin

10.90%

N/A

Market Cap

$163.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.35M

N/A

Employees

121

N/A

Net Income

-$7.39M

+44.5%

EBITDA

-$9.06M

-85.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$35.34M

+9.0%

Total Debt

$9.54M

+7.3%

Accounts Receivable

$3.49M

-48.6%

Inventory

$4.12M

+7.1%

Long Term Debt

$8.61M

+6.6%

Short Term Debt

$932.00K

+13.4%

Return on Assets

-28.07%

N/A

Return on Invested Capital

-59.58%

N/A

Free Cash Flow

-$10.06M

-47.8%

Operating Cash Flow

-$8.99M

-56.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AARDAardvark Therapeutics, Inc. Common Stock
$6.10+5.35%
NTHINeonc Technologies Holdings, Inc.
$4.94+5.33%
EPRXEupraxia Pharmaceuticals Inc.
$6.46-3.22%
TARAProtara Therapeutics, Inc.
$3.86+1.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About MDWD

What is the current price of MediWound?

MediWound is trading at $12.61 per share.

What is the 52-week range for MediWound?

Over the past 52 weeks, MediWound has traded between $12.52 and $20.30.

How much debt does MediWound have?

As of the most recent reporting period, MediWound reported total debt of $9.54M.

How much cash does MediWound have on hand?

MediWound reported $4.34M in cash and cash equivalents in its most recent financial results.

What is MediWound’s dividend yield?

MediWound does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services